Suppr超能文献

溃疡性肠结核作为英夫利昔单抗治疗肠道白塞病的并发症:一例报告。

Ulcerative intestinal tuberculosis case as a complication of treatment by infliximab for intestinal Behçet's disease: A case report.

作者信息

Shen Yan, Ma Hai-Fen, Yang Yan-Li, Guan Jian-Long

机构信息

Rheumatology and Immunology Department.

Medical Imaging Department, Huadong Hospital, Fudan University, Shanghai 200040, PR China.

出版信息

Medicine (Baltimore). 2019 Oct;98(43):e17652. doi: 10.1097/MD.0000000000017652.

Abstract

RATIONALE

Intestinal Behçet's disease (BD) is characterized by intestinal ulcerations and gastrointestinal symptoms. Ulcerative intestinal tuberculosis (TB) is usually with dyspepsia, abdominal pain, vomiting, and weight loss. The 2 diseases exhibit similar clinical manifestations, but the most critical aspects of their clinical courses and required treatments are not at all similar.

PATIENT CONCERNS

We present a case in which a patient with intestinal Behçet's disease developed a de novo ulcerative intestinal TB infection after the start of anti-tumor necrosis factor-α treatment. This was despite histopathologic examination without caseous necrosis granuloma and negative for acid-fast staining and latent TB screen.

DIAGNOSES

Intestinal Behçet's disease and intestinal TB.

INTERVENTIONS

The patient was treated with quadruple antituberculous chemotherapy, comprising rifapentine, isoniazid, ethambutol, and pyrazinamide.

OUTCOMES

At follow-up about 3 months, the therapy of oral antituberculous drugs and thalidomide was continued and the patient's condition had stabilized.

LESSONS

This case illustrates the importance of closely monitoring patients who are on infliximab for possible onset of TB, even without abdominal symptoms, and with negative screening results for latent TB.

摘要

原理

肠道白塞病(BD)的特征是肠道溃疡和胃肠道症状。溃疡性肠结核(TB)通常伴有消化不良、腹痛、呕吐和体重减轻。这两种疾病表现出相似的临床表现,但它们临床病程的最关键方面和所需治疗方法却完全不同。

患者情况

我们报告一例肠道白塞病患者在开始抗肿瘤坏死因子-α治疗后新发溃疡性肠结核感染的病例。尽管组织病理学检查未发现干酪样坏死肉芽肿,抗酸染色阴性且潜伏性结核筛查阴性。

诊断

肠道白塞病和肠结核。

干预措施

患者接受了包含利福喷丁、异烟肼、乙胺丁醇和吡嗪酰胺的四联抗结核化疗。

结果

在约3个月的随访中,继续口服抗结核药物和沙利度胺治疗,患者病情已稳定。

经验教训

该病例说明了即使没有腹部症状且潜伏性结核筛查结果为阴性,对接受英夫利昔单抗治疗的患者密切监测是否可能发生结核病的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ff/6824802/7eaea4ae5e28/medi-98-e17652-g001.jpg

相似文献

3
Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Dig Liver Dis. 2019 Jul;51(7):967-971. doi: 10.1016/j.dld.2018.10.024. Epub 2019 Feb 19.
5
Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
Gut Liver. 2018 Nov 15;12(6):623-632. doi: 10.5009/gnl17462.
10
Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6. doi: 10.1007/s10384-006-0425-y. Epub 2007 Jun 7.

本文引用的文献

1
Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
Dig Dis Sci. 2017 Feb;62(2):441-447. doi: 10.1007/s10620-016-4395-8. Epub 2017 Jan 2.
3
4
Clinicopathological profile of patients with abdominal tuberculosis.
J Nepal Health Res Counc. 2011 Oct;9(2):169-75.
5
Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
Mod Rheumatol. 2011 Apr;21(2):184-91. doi: 10.1007/s10165-010-0370-y. Epub 2010 Nov 5.
6
Multi-site abdominal tuberculosis mimics malignancy on 18F-FDG PET/CT: report of three cases.
World J Gastroenterol. 2010 Sep 7;16(33):4237-42. doi: 10.3748/wjg.v16.i33.4237.
8
Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.
Inflamm Bowel Dis. 2008 Sep;14(9):1259-64. doi: 10.1002/ibd.20457.
9
Intestinal tuberculosis in a patient on infliximab treatment.
Gastrointest Endosc. 2008 Jun;67(7):1178-9; discussion 1179. doi: 10.1016/j.gie.2007.12.048. Epub 2008 Mar 7.
10
Adverse reactions to biologic agents: focus on autoimmune disease therapies.
J Allergy Clin Immunol. 2005 Oct;116(4):900-5. doi: 10.1016/j.jaci.2005.03.028.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验